• small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

2014 News Releases

Webcast ImageWebcast
MIMEDX GROUP INC Q3 2014 Earnings Conference Call  (Live)
Oct 30, 2014 at 10:30 a.m. ET
MIMEDX GROUP INC Q3 2014 Earnings Conference Call
Thursday, October 30, 2014 10:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2014 | 2013 | 2012 | 2011
DateTitle 
Oct 21, 2014MiMedx Provides Update On Outstanding Patent Litigation
MARIETTA, Ga., Oct. 21, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, issued an update on its outstanding patent litigations. MiMedx has repeatedly stated that it will vigorously defend and enforce its patent portfol... 
Printer Friendly Version
Oct 16, 2014MiMedx At Fall 2014 SAWC: Studies And Key Opinion Leaders Present Clinical Evidence Of EpiFix Healing Results On Chronic And Acute Wounds
EpiFix® shown to result in the most rapid improvement and resolution of DFUs, successful complex management of extensive life-threatening wounds, and safe and effective treatment of Stage IV Pressure Ulcers MARIETTA, Ga., Oct. 16, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG) EpiFix® dehydrated human amnion/chorion membrane (dHACM) allografts have been shown to be clinically effective in the treatment of hard-to-heal wounds such as diabetic foot ulcers (DFUs), pressure ulcers (PrUs),... 
Printer Friendly Version
Oct 13, 2014MiMedx Third Quarter Revenue Of $33.5 Million Exceeds Upper End Of Guidance
Revenue Increases 31% sequentially and 108% over 2013 third Quarter and Company records first quarterly operating profit Company Provides Preliminary Insight into 2015 Revenue and Operating Profit Margin MARIETTA, Ga., Oct. 13, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, S... 
Printer Friendly Version
Oct 06, 2014MiMedx Announces Release Date for 2014 Third Quarter Results
MARIETTA, Ga., Oct. 6, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare,  announced today that its results for the third quarter, ended September 30, 2014, will be released before the opening of the market on Thursday, Octo... 
Printer Friendly Version
Sep 30, 2014MiMedx to Present at the Stem Cell Meeting on the Mesa
MARIETTA, Ga., Sept. 30, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Dr. Tom Koob, Ph.D., Chief Scientific Officer, will present at the Stem Cell Meeting on the Mesa. Dr. Koob will present on Tues... 
Printer Friendly Version
Sep 24, 2014Study Determines MiMedx Allograft Effectively Recruits Circulating Stem and Progenitor Cells
MARIETTA, Ga., Sept. 24, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the publication of its latest peer-reviewed scientific study, "Progenitor Cell Recruitment By Dehydrated Human Amnion Chorion Grafts Promotes Neovascularization in a Murine Model of Dermal Ischemia", was electronically published in the Journal... 
Printer Friendly Version
Sep 18, 2014MiMedx Signs Distribution Agreement With Zimmer
MARIETTA, Ga., Sept. 18, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Zimmer, Inc.  Through the agreement, MiMedx will provide its dehydrated human amnion/chorion membrane ("dHACM") allograft products to Zimmer to be marketed non- exclusively on a private label basis.... 
Printer Friendly Version
Sep 17, 2014MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal
VLU STUDY PATIENTS TREATED WITH EPIFIX® ALLOGRAFT HAD DOUBLE THE RATE OF WOUND CLOSURE COMPARED TO CONTROL GROUP MARIETTA, Ga., Sept. 17, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the publication of another peer-reviewed clinical study.    The study article, "A Multi-center Randomized Controlled Clinical Trial Ev... 
Printer Friendly Version
Sep 08, 2014MiMedx To Webcast Its Analyst Day On October 14th
MARIETTA, Ga., Sept. 8, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer  of  patent  protected  regenerative  biomaterials  and bioimplants processed from human amniotic membrane, announced today that it will be hosting and webcasting its Analyst Day on Tuesday, October 14, 2014, in New York, New York.  Parker H. "Pete" Petit, Chairman and CEO; William C. Taylor, President and COO; Michael J. Senken, Chief Financial Officer; and other membe... 
Printer Friendly Version
Sep 03, 2014Fifth MiMedx Scientific Study Published In Peer-Reviewed Journal
Study determines allografts with both amnion and chorion contain approximately 20 times more cytokines than the competitive single layer amnion allografts evaluated MARIETTA, Ga., Sept. 3, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the publication of another peer-reviewed scientific study in the scientific literature... 
Printer Friendly Version
Aug 04, 2014MiMedx To Present At 34th Annual Canaccord|Genuity Growth Conference
MARIETTA, Ga., Aug. 4, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 34th Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present... 
Printer Friendly Version
Jul 28, 2014MiMedx Announces Record Second Quarter Results
Revenue Increases by 89% Over 2013 Second Quarter MARIETTA, Ga., July 28, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended June 30, 2014. Highlights include: Revenue exceeds upper end of guidance and increases by 89% over Q2 2013 to $25.6 million Quarter-over-quarter ... 
Printer Friendly Version
Jul 23, 2014MiMedx Files Its Initial Investigational New Drug Application
MARIETTA, Ga., July 23, 2014 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, processor and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it has filed its initial Investigational New Drug ("IND") application with the Food and Drug Administration ("FDA").   The IND submission, which was filed yesterday, July 22, 2014, is the Company's initial submission for certain indications of its mi... 
Printer Friendly Version
Jul 22, 2014Restrospective Analysis Finds MiMedx EpiFix® As Most Effective In Rapid Resolution Of Diabetic Foot Ulcers When Compared With Two Other Skin Substitutes
EpiFix® shown to have most rapid and complete wound healing, least wastage and lowest cost per patient among three advanced wound care products in retrospective analysis of data. MARIETTA, Ga., July 22, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced for investors today that a peer-reviewed study, "An Evaluation of Healing Metr... 
Printer Friendly Version
Jul 15, 2014MiMedx Announces Release Date For 2014 Second Quarter Results
MARIETTA, Ga., July 15, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the second quarter, ended June 30, 2014, will be released before the opening of the market on Tuesday, July 29, 2014.  MiMedx will host a live broadcast of its second quarter conference call on Tuesday, July 29, 2014, at 10:30am EDT.... 
Printer Friendly Version
Jul 14, 2014MiMedx Announces Revised Local Coverage Determination From Medicare Contractor That Includes EpiFix®
MARIETTA, Ga., July 14, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Medicare Administrative Contractor responsible for Jurisdiction H, which has approximately five million beneficiaries in Texas, Oklahoma, Louisiana, New Mexico, Colorado, Mississippi and Arkansas, has revised its Local Coverage Determination (LC... 
Printer Friendly Version
Jun 19, 2014MiMedx Expects To File Its First Investigational New Drug Application In July
Company Adds Key Executives to Support its IND and BLA Initiatives MARIETTA, Ga., June 19, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it expects to file its first Investigational New Drug ("IND") application with the Food and Drug Administration ("FDA") during the month of July 2014. The IND submission is the Company... 
Printer Friendly Version
Jun 19, 2014MiMedx Increases Guidance For Second Quarter And Full Year 2014
Second Quarter Revenue Estimated to Range from $24 Million to $25 Million MARIETTA, Ga., June 19, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its revised guidance for the second quarter of 2014 and full year 2014. Parker H. "Pete" Petit, Chairman and CEO, said, "Our sales organization continues to perform very eff... 
Printer Friendly Version
Jun 04, 2014MiMedx Board Applauds Dismissal Of Lawsuit Against Chairman & CEO
MARIETTA, Ga., June 4, 2014 /PRNewswire/ -- The Board of Directors of MiMedx Group, Inc. (NASDAQ: MDXG), announced today that the Board applauds the dismissal of the lawsuit brought by the Securities and Exchange Commission ("SEC") against the Company's Chairman and CEO, Parker H. "Pete" Petit. The SEC had brought a civil action against Mr. Petit alleging that in 2007, when he was Chairman and CEO of Matria Healthcare, Inc. (NASDAQ: MATR), he provided inside information to a friend who subse... 
Printer Friendly Version
May 27, 2014MiMedx Increases Lower End Of Guidance For Second Quarter And Full Year 2014
Company Provides Insight into 2015 Revenue Opportunities MARIETTA, Ga., May 27, 2014 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, processor and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its revised guidance for the second quarter of 2014 and full year 2014, and provided insight onto various factors influencing the Company's revenue opportunities in 2015 and beyond.   Parker ... 
Printer Friendly Version
May 23, 2014MiMedx to Present at the Jefferies 2014 Healthcare Conference
MARIETTA, Ga., May 23, 2014 /PRNewswire/ -- MiMedx (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the Jefferies 2014 Healthcare Conference in New York, New York.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, June 3, 2014 ... 
Printer Friendly Version
May 20, 2014MiMedx Declines To Participate In NAD Review Proceeding
MARIETTA, Ga., May 20, 2014 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it has declined to participate in the adjudication of an advertising challenge filed with the National Advertising Division of the Council of Better Business Bureaus (NAD).  The NAD administers a self-regulation program designed to ensure the integrity a... 
Printer Friendly Version
May 15, 2014MiMedx To Present At The 11th Annual Craig-Hallum Institutional Investor Conference
MARIETTA, Ga., May 15, 2014 /PRNewswire/ -- MiMedx (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 11th Annual Craig-Hallum Institutional Investor Conference in Minneapolis, Minnesota.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to partici... 
Printer Friendly Version
May 12, 2014MiMedx Announces $10 Million Stock Repurchase Program
MARIETTA, Ga., May 12, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its Board of Directors has approved a stock repurchase program. Under the terms of the program, the Company may repurchase up to $10 million of its common stock from time to time through December 31, 2014. The timing and amount of repurchases, if any, ... 
Printer Friendly Version
May 06, 2014Two New MiMedx Scientific Studies Published In Peer-Reviewed Journals
MARIETTA, Ga., May 6, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that two of its peer-reviewed scientific studies have been published in the scientific literature. The Company's study "Angiogenic Properties of Dehydrated Human Amnion/Chorion Allografts: Therapeutic Potential for Soft Tissue Repair and Regeneratio... 
Printer Friendly Version
Apr 29, 2014MiMedx Issued Four New U.S. Patents For Placental Tissue Allografts
Company Amends its Patent Infringement Lawsuit to Include Two Additional Patents MARIETTA, Ga., April 29, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of four newly issued patents related to the Company's tissue allografts derived from the placenta. On April 22, 2014, the U.S. Patent and Trademark Of... 
Printer Friendly Version
Apr 25, 2014MiMedx Announces Record Quarterly Results
Revenue Increases by 69% Over 2013 First Quarter MARIETTA, Ga., April 25, 2014 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended March 31, 2014. Highlights include: Revenue exceeds upper end of guidance and increases by 69% over Q1 2013 10th consecutive quarter of meeting or exceed... 
Printer Friendly Version
Apr 23, 2014MiMedx at SAWC Spring 2014: Multiple Studies And Clinical Experience Demonstrate Clinical And Cost Effectiveness Of EpiFix Allograft For Treatment Of Hard-to-Heal Wounds
EpiFix® is shown to promote rapid healing and return to function for patients and provide a potential for significant cost savings. MARIETTA, Ga., April 23, 2014 /PRNewswire/ -- EpiFix®, dehydrated human amnion/chorion membrane (dHACM) allografts, were shown to be clinically and cost effective in the treatment of multiple hard-to-treat wounds like diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers (PUs), according to data and case experiences being presented at the Spr... 
Printer Friendly Version
Apr 22, 2014MiMedx Files Lawsuit Against Liventa, Medline, And Musculoskeletal Transplant Foundation
MARIETTA, Ga., April 22, 2014 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has filed a patent infringement lawsuit against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages. In ad... 
Printer Friendly Version
Apr 21, 2014MiMedx Sponsors Scott Rigsby, Double-Amputee
MARIETTA, Ga., April 21, 2014 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its sponsorship of Scott Rigsby, a double-amputee athlete. As part of the relationship, Rigsby will be taking his "inspire, inform, enable" message to Boston as he returns to run the 2014 Boston Marathon on April 21. Rigsby was 18 when he lost h... 
Printer Friendly Version
Apr 07, 2014MiMedx First Quarter Revenue Exceeded Upper End Of Guidance
COMPANY ANNOUNCES SECOND QUARTER REVENUE GUIDANCE MARIETTA, Ga., April 7, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its first quarter of 2014 revenue slightly exceeded the upper end of its previously announced guidance. The Company also announced its guidance for the second quarter of 2014.... 
Printer Friendly Version
Apr 02, 2014MiMedx Group, Inc. Announces Release Date for 2014 First Quarter Results
MARIETTA, Ga., April 2, 2014 /PRNewswire/ -- MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the first quarter ended March 31, 2014, will be released before the opening of the market on Friday, April 25, 2014.  MiMedx will host a live broadcast of its first quarter conference call on Friday, April 25, 2014 at 10:30am EDT.   A listen-... 
Printer Friendly Version
Mar 28, 2014MiMedx to Present at the 13th Annual Needham Healthcare Conference
MARIETTA, Ga., March 28, 2014 /PRNewswire/ -- MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent  protected  regenerative  biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 13th Annual Needham Healthcare Conference in New York, New York.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, ... 
Printer Friendly Version
Mar 24, 2014MiMedx Schedules Shareholder Call To Update Progress Of FDA Discussions, Reimbursement Successes And Recent Short-Selling Initiatives
COMPANY ALSO RAISES LOWER END OF 2014 REVENUE GUIDANCE MARIETTA, Ga., March 24, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it will host a shareholder call tomorrow, Tuesday, March 25, 2014 at 11:00 AM Eastern Time to update shareholders on the positive progress of its discussions with the Foo... 
Printer Friendly Version
Mar 17, 2014MiMedx to Present at 2nd Annual Regen Med Investor Day
MARIETTA, Ga., March 17, 2014 /PRNewswire/ -- MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 2nd Annual Regen Med Investor Day in New York, New York.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Wednesday, March 26t... 
Printer Friendly Version
Mar 13, 2014MiMedx EpiFix® Allograft Receives Medicare Coverage From The Final Medicare Contractor
EpiFix® Now Has Coverage From All Medicare Contractors In All 50 states MARIETTA, Ga., March 13, 2014 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, First Coast Service Options, Inc. ("FCSO"), has confirmed that the Company's wound care allograft, EpiFix®, has been approved for coverage when appl... 
Printer Friendly Version
Mar 04, 2014MiMedx To Present At 2014 Canaccord Genuity Musculoskeletal Conference
THE COMPANY TO EXHIBIT AT THE AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS (AAOS) MARIETTA, Ga., March 4, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer  of  patent  protected  regenerative  biomaterials  and bioimplants processed from human amniotic membrane, announced today that it will present at the 2014 Canaccord|Genuity Musculoskeletal Conference in New Orleans, Louisiana.  Parker H. "Pete" Petit, Chairman and CEO, William C. T... 
Printer Friendly Version
Feb 26, 2014MiMedx Announces Record 2013 Results
... 
Printer Friendly Version
Feb 25, 2014MiMedx Sponsored Osteoarthritis Study Using PURION® Processed Amniotic Tissue Published In Arthritis Research & Therapy
THE JOURNAL ENTITLED "NATURE REVIEWS RHEUMATOLOGY" HIGHLIGHTS THIS PUBLICATION MARIETTA, Ga., Feb. 25, 2014 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today a MiMedx-sponsored study from Georgia Institute of Technology has been published in Arthritis Research & Therapy.  The article, titled "Intra-articular injection of... 
Printer Friendly Version
Feb 25, 2014Second MiMedx EpiFix® Randomized Comparative Study Published In International Wound Journal Shows 92.5% Healing Rate Over 12 Weeks
37 Of 40 Hard To Heal Wounds Closed In 12 Weeks MARIETTA, Ga., Feb. 25, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "A prospective, randomized comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers" has b... 
Printer Friendly Version
Feb 12, 2014MiMedx EpiFix® Allograft Awarded Coverage by HCSC
MARIETTA, Ga., Feb. 12, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Health Care Services Corporation (HCSC) has confirmed that the Company's EpiFix® allograft has been awarded reimbursement coverage. HCSC is the largest customer-owned health insurance company in the United States with nearly 14 million members. ... 
Printer Friendly Version
Feb 10, 2014MiMedx EpiFix® Allograft Receives Reimbursement Coverage From The 7th Of The 8 Medicare Contractors
EPIFIX® NOW HAS MEDICARE COVERAGE IN 49 OF 50 STATES MARIETTA, Ga., Feb. 10, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, Noridian Healthcare Solutions, LLC, has confirmed that the Company's wound care allograft, EpiFix®, has been approved to receive reimbursement coverage. The coverage ... 
Printer Friendly Version
Feb 07, 2014MiMedx Addresses Misrepresentations In Seeking Alpha Article
MARIETTA, Ga., Feb. 7, 2014 /PRNewswire/ -- MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, today issued the following statement regarding a blog post published today on Seeking Alpha. Shareholders should not rely on Seeking Alpha type articles regardless of whether they are positive or negative. The primary source of information should be the Company's filings and p... 
Printer Friendly Version
Jan 21, 2014MiMedx Announces Release Date For 2013 Full Year Results
MARIETTA, Ga., Jan. 21, 2014 /PRNewswire/ -- MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the fourth quarter and year ended December 31, 2013, will be released before the opening of the market on Wednesday, February 26, 2014.  MiMedx will host a live broadcast of its fourth quarter and year-end conference call on Wednesday, Februa... 
Printer Friendly Version
Jan 13, 2014MiMedx to Present at 32nd Annual J.P. Morgan Healthcare Conference
MARIETTA, Ga., Jan. 13, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced the schedule for its presentation at the 32nd Annual J.P. Morgan Healthcare Conference.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, will present on Thursday, January 16, 20... 
Printer Friendly Version

Products

CONTACT US

888.543.1917